SCHEMBL10196910

SCHEMBL10196910

O=c1c(Cc2cccc(O)c2)nc2c(Cc3ccccc3)[nH]c(-c3ccc(O)cc3)cn1-2

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.38
▸ MTOR P42345 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ ABCB1 P08183 1/20 0.37
▸ CDC7 O00311 2/20 0.37
▸ GAA P10253 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ ADORA3 P0DMS8 2/20 0.34
▸ ADORA1 P30542 2/20 0.34
▸ XDH P47989 1/20 0.33
▸ LTB4R Q15722 1/20 0.33
▸ CASR P41180 1/20 0.33
▸ CXCR2 P25025 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ IDH1 O75874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19206714 0.96 ALDH1A1 (0.38) PARP1ALDH1A1CDC7GAAPKM
SCHEMBL954434 0.94 ABCB1 (0.41) PARP1MTORALDH1A1ABCB1CDC7
SCHEMBL64690 0.93 ABCB1 (0.42) PARP1MTORALDH1A1ABCB1CDC7
SCHEMBL12293879 0.93 ABCB1 (0.42) PARP1MTORALDH1A1ABCB1CDC7
SCHEMBL30800148 0.92 ADORA3 (0.39) PARP1MTORALDH1A1ABCB1CDC7
SCHEMBL21751454 0.92 ADORA3 (0.39) PARP1MTORALDH1A1ABCB1CDC7
SCHEMBL10196901 0.91 THRB (0.38) PARP1ABCB1CDC7ADORA1ADORA2A
SCHEMBL21751336 0.91 ADORA3 (0.41) PARP1ALDH1A1CDC7GAAPKM
SCHEMBL2680751 0.91 ABCB1 (0.40) PARP1ALDH1A1ABCB1CDC7GAA
SCHEMBL10196956 0.90 ABCB1 (0.38) PARP1ALDH1A1ABCB1CDC7ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9645128-B2 Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity JNC CORPORATION (JP) 2017-05-09 — — US disclosed
US-9645128-B2 Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity JNC CORPORATION (JP) 2017-05-09 — — US disclosed
US-20150344936-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2015-12-03 — — US disclosed
US-20150344936-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2015-12-03 — — US disclosed
US-9151739-B2 Coelenterazine analogs and manufacturing method thereof JNC CORPORATION (JP) 2015-10-06 — — US disclosed
US-9151739-B2 Coelenterazine analogs and manufacturing method thereof JNC CORPORATION (JP) 2015-10-06 — — US disclosed
US-20140296521-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF JNC CORP (JP) 2014-10-02 — — US disclosed
US-20140296521-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF JNC CORP (JP) 2014-10-02 — — US disclosed
US-8765921-B2 Coelenterazine analogs and manufacturing method thereof JNC CORPORATION (JP) 2014-07-01 — — US disclosed
US-8765921-B2 Coelenterazine analogs and manufacturing method thereof JNC CORPORATION (JP) 2014-07-01 — — US disclosed
US-20140024058-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2014-01-23 — — US disclosed
US-20140024058-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2014-01-23 — — US disclosed
US-8546568-B2 Coelenterazine analogs and manufacturing method thereof JNC CORPORATION (JP) 2013-10-01 — — US disclosed
US-8546568-B2 Coelenterazine analogs and manufacturing method thereof JNC CORPORATION (JP) 2013-10-01 — — US disclosed
US-20120035070-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2012-02-09 — — US disclosed
US-20120035070-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2012-02-09 — — US disclosed
WO-2010090319-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF チッソ株式会社 (JP) 2010-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296521-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF GLB1, CEL, SI PARP1 4040/4885MTOR 4256/4885ALDH1A1 1342/4885
US-20120035070-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF GLB1, CEL, SI PARP1 4040/4885MTOR 4256/4885ALDH1A1 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback